Dipal Doshi is CEO of Entrada Therapeutics, Inc.. Currently has a direct ownership of 325,753 shares of TRDA, which is worth approximately $5.66 Million. The most recent transaction as insider was on Jun 27, 2022, when has been sold 4,000 shares (Common Stock) at a price of $12.0 per share, resulting in proceeds of $48,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 326K
0% 3M change
32.81% 12M change
Total Value Held $5.66 Million

Dipal Doshi Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 27 2022
SELL
Open market or private sale
$48,000 $12.0 p/Share
4,000 Reduced 1.86%
210,710 Common Stock
Mar 01 2022
BUY
Grant, award, or other acquisition
-
30,250 Added 12.35%
214,710 Common Stock
Jan 13 2022
BUY
Exercise of conversion of derivative security
$17,400 $1.74 p/Share
10,000 Added 5.14%
184,460 Common Stock
DD

Dipal Doshi

CEO
Boston, MA

Track Institutional and Insider Activities on TRDA

Follow Entrada Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TRDA shares.

Notify only if

Insider Trading

Get notified when an Entrada Therapeutics, Inc. insider buys or sells TRDA shares.

Notify only if

News

Receive news related to Entrada Therapeutics, Inc.

Track Activities on TRDA